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Objectives: This study aimed to predict trimethoprim/sulfamethoxazole (SXT) resistance in patients with
community-onset urinary tract infection (UTI) due to Enterobacteriaceae based on patient-speciﬁc risk
factors.
Methods: This was a retrospective case–control study in Prisma Health facilities in central South Carolina,
USA, including three community hospitals, afﬁliated emergency departments and ambulatory clinics,
including adult patients with community-onset UTI due to Enterobacteriaceae (1 April 2015 to 29
February 2016). Multivariate logistic regression was used to examine risk factors for SXT resistance.
Results: Among 351 unique patients with community-onset UTI, 71 (20.2%) had SXT-resistant
Enterobacteriaceae urinary isolates. Overall, median age was 64 years and 252 (71.8%) were female. A
multivariate model identiﬁed prior urinary infection/colonisation with SXT-resistant Enterobacteriaceae
(OR = 8.58, 95% CI 3.92–18.81; P < 0.001) and SXT use within past 12 months (OR = 2.58, 95% CI 1.13–5.89;
P = 0.02) as predictors of SXT resistance among urinary isolates. Most patients with UTI (285; 81.2%) had
no risk factors for SXT resistance. SXT resistance rates increased from 13% in the absence of risk factors to
31% in patients with prior SXT use, 66% in those with prior urinary infection/colonisation with SXTresistant Enterobacteriaceae and 73% in the presence of both risk factors.
Conclusion: SXT resistance in Enterobacteriaceae urinary isolates may be predicted based on prior urine
culture results and SXT use within the previous year. Utilisation of a patient-speciﬁc antibiogram may
allow empirical SXT use in patients with community-onset UTI in the absence of risk factors for
resistance.
© 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction

$
The results of this study were presented in part at the 2017 American College of
Clinical Pharmacy (ACCP) Annual Meeting, 7–10 October 2017, Phoenix, AZ, USA
[abstract #206E].
* Corresponding author at: University of South Carolina School of Medicine,
Columbia, SC, USA.
E-mail address: majdi.alhasan@uscmed.sc.edu (M.N. Al-Hasan).
1
Present address: Department of Pharmacy, Morton Plant Hospital, Clearwater,
FL, USA.
2
Present address: Department of Pharmacy, Novant Health Presbyterian
Hospital, Charlotte, NC, USA.
3
Present address: Department of Pharmacy, University of Virginia Health,
Charlottesville, VA, USA.

Urinary tract infections (UTIs) are among the most commonly
encountered infections both in community and hospital settings
[1]. Increasing antimicrobial resistance (AMR) rates among
Escherichia coli, the predominant urinary pathogen, has limited
oral antimicrobial treatment options for UTIs [2,3]. Although
nitrofurantoin and fosfomycin remain the preferred agents for the
treatment of uncomplicated cystitis, their use may be limited in
many patients owing to, respectively, low creatinine clearance and
concerns for reduced efﬁcacy [4–8]. International management
guidelines recommend against the use of trimethoprim/sulfamethoxazole (SXT) in acute cystitis if the resistance rate among
local urinary isolates is 20% [4]. However, SXT resistance rates
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among E. coli isolates across the USA and most of Europe have
exceeded 20% [2,9,10]. Avoiding SXT use in patients with acute
cystitis who may not be candidates for nitrofurantoin or
fosfomycin therapy owing to either cost or the above clinical
concerns may encourage utilisation of broader-spectrum and more
toxic antimicrobial agents such as ﬂuoroquinolones and cephalosporins.
Selection of an oral antimicrobial regimen for acute pyelonephritis is an even more complex decision owing to the greater
severity of these infections and increasing AMR rates of E. coli
isolates to all oral agents, including ﬂuoroquinolones, SXT and βlactams [2,3,9–11].
Several clinical tools for prediction of AMR based on patientspeciﬁc risk factors have recently been described in order to
improve empirical antimicrobial selection in patients with
bacterial infections [12–14]. More speciﬁcally, one study proposed
the optimisation of ambulatory antimicrobial management of
acute pyelonephritis by utilisation of a ﬂuoroquinolone resistance
score that predicts the probability of ﬂuoroquinolone resistance
based on patient-speciﬁc risk factors [15]. None the less, neither
this approach nor the international management guidelines offer
alternative oral options for treatment of acute pyelonephritis in
patients with major risk factors for ﬂuoroquinolone resistance
[4,15].
The purpose of this retrospective case–control study was to
develop a stratiﬁed antibiogram for prediction of SXT resistance
among Enterobacteriaceae urinary isolates in patients with
community-onset UTI.
2. Materials and methods
2.1. Setting
This study was conducted at Prisma Health inpatient and
outpatient facilities in central South Carolina, USA, including three
community hospitals, three emergency departments and several
afﬁliated urgent treatment centres and ambulatory clinics. Prisma
Health is the largest healthcare provider in the Midlands region of
central South Carolina. The study was approved by the Institutional
Review Board at Prisma Health, who waived informed consent.
2.2. Deﬁnitions
UTI was deﬁned as the presence of urinary symptoms or signs
and monomicrobial growth of bacteria in urine culture obtained
during the index healthcare visit. Complicated UTI (cUTI) was
deﬁned as obstructive uropathy, indwelling urinary catheter,
urinary retention due to neurological disease, or bladder outlet
obstruction [16,17]. Patients with clinical manifestations of acute
pyelonephritis, including temperature >38  C, unilateral ﬂank pain
or costovertebral angle tenderness, were also considered to have
cUTI [18]. Prior antimicrobial therapy was deﬁned as using the
respective antimicrobial agent or class for >24 h within the past 12
months from collection of the index urine culture. SXT-resistant
(SXT-R) Enterobacteriaceae were deﬁned as isolates with a
minimum inhibitory concentration (MIC) 4/76 mg/mL according
to the Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoint [19]. Nitrofurantoin susceptibility was also
determined for 340 urinary isolates, with non-susceptible isolates
being deﬁned as those with an MIC 64 mg/mL [19].
2.3. Case ascertainment
All patients aged 18 years with growth of Gram-negative
bacilli in urine culture obtained at ambulatory facilities or within
48 h of hospitalisation during the period 1 April 2015 to 29
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February 2016 were retrospectively identiﬁed through an alert
system that interfaced with the central microbiology laboratory at
Prisma Health (n = 1071). Patients with asymptomatic bacteriuria
(n = 404), polymicrobial growth of bacteria in urine culture
(n = 202), growth of a lactose-non-fermenting bacterium in urine
culture (n = 103) and recurrent episodes of positive urine cultures
during the study period (n = 11) were excluded from the study.
Thus, a total of 351 unique adults with community-onset UTI due
to Enterobacteriaceae were included in the analysis. Patient
demographics as well as microbiological and clinical data,
including potential risk factors for AMR, were collected from the
electronic medical records. Prior antimicrobial use was obtained
from medication administration records, electronic prescriptions,
external prescription records provided by community pharmacies
and pharmacy beneﬁt managers, and clinical notes from prior
hospitalisations or visits to afﬁliated hospitals, emergency departments and other ambulatory settings.
2.4. Statistical analysis
Logistic regression was used to examine risk factors for SXT
resistance in patients with UTI in a case–control design.
Demographic and clinical variables were collected in patients
with UTI due to SXT-R (cases) and SXT-susceptible (SXT-S)
Enterobacteriaceae (controls). Collected variables included age,
sex, ethnicity, diabetes mellitus, cancer, immunocompromised
host [e.g. active cancer/receiving chemotherapy, human immunodeﬁciency virus/acquired immune deﬁciency syndrome (HIV/
AIDS), solid-organ transplant recipient, documented immunosuppressive therapy], recent hospitalisation within 3 months, residence in a skilled nursing facility, ambulatory gastrointestinal or
genitourinary procedure within 1 month, prior UTI or urinary
colonisation with SXT-R bacteria within 12 months, and prior
antimicrobial use within 12 months. Variables associated with SXT
resistance in the univariate logistic regression model with P < 0.10
were included in the multivariate logistic regression model to
identify independent risk factors for SXT resistance. The odds ratio
with 95% conﬁdence interval were reported to demonstrate the
strength of association between each risk factor and SXT
resistance.
A stratiﬁed antibiogram of Enterobacteriaceae urinary isolates
based on patient-speciﬁc risk factors for SXT resistance was
developed to evaluate selection of SXT for empirical antimicrobial
therapy in patients with UTI.
JMP Pro v.12.1 (SAS Institute Inc., Cary, NC, USA) was used for
statistical analysis. The level of signiﬁcance for statistical testing
was deﬁned as P  0.05 (two-sided) unless otherwise speciﬁed.
3. Results
During the study period, 351 unique patients with UTI due to
Enterobacteriaceae were identiﬁed and were included in the
analysis. Overall, the median age was 64 years, 252 (71.8%) were
female and 142 (40.2%) had a cUTI. Escherichia coli was the most
common urinary isolate (214; 61.0%), followed by Klebsiella spp.
(53; 15.1%), Proteus mirabilis (51; 14.5%), Enterobacter spp. (19;
5.4%), Serratia spp. (8; 2.3%) and other Enterobacteriaceae (6;
1.7%). Moreover, 71 patients (20.2%) had a UTI due to SXT-R
bacteria and the remaining 280 (79.8%) had a UTI due to SXT-S
bacteria.
The baseline demographic and clinical characteristics of the
patients with community-onset UTI caused by SXT-S and SXT-R
bacteria are shown in Table 1. Univariate logistic regression
identiﬁed immunocompromised status, recent hospitalisation
within previous 3 months, prior UTI or urinary colonisation with
SXT-R bacteria, and prior use both of SXT and ﬂuoroquinolones
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Table 1
Demographic and clinical characteristics of patients with community-onset urinary tract infection and risk factors for trimethoprim/sulfamethoxazole (SXT) resistance in the
univariate model.a
Characteristic

SXT-R (n = 71)

SXT-S (n = 280)

OR (95% CI)

P-value

Age (years) [median (IQR)]
Female sex
Ethnicity
White
African-American
Other
Diabetes mellitus
Cancer
Immunocompromised status
Presence of Foley catheter
Residence at nursing facility
Recent hospitalisationb
Recent outpatient procedurec
Prior urinary infection/colonisation with SXT-R bacteriad
Prior antimicrobial used
SXT
Fluoroquinolones
β-Lactams

64 (48–76)
51 (71.8)

64 (50–80)
201 (71.8)

0.99 (0.87–1.12)
1.00 (0.56–1.79)

0.84
0.99

36 (50.7)
32 (45.1)
3 (4.2)
29 (40.8)
11 (15.5)
10 (14.1)
10 (14.1)
11 (15.5)
29 (40.8)
4 (5.6)
27 (38.0)

115 (41.1)
141 (50.4)
24 (8.6)
88 (31.4)
31 (11.1)
19 (6.8)
48 (17.1)
35 (12.5)
70 (25.0)
8 (2.9)
13 (4.6)

1.48 (0.88–2.49)

0.14

1.51 (0.88–2.58)
1.47 (0.70–3.10)
2.24 (0.99–5.07)
0.79 (0.38–1.66)
1.28 (0.62–2.67)
2.07 (1.20–3.57)
2.03 (0.59–6.94)
12.60 (6.05–26.27)

0.13
0.31
0.05
0.54
0.51
0.009
0.26
<0.001

16 (22.5)
22 (31.0)
12 (16.9)

21 (7.5)
32 (11.4)
66 (23.6)

3.59 (1.76–7.32)
3.48 (1.87–6.49)
0.66 (0.33–1.30)

<0.001
<0.001
0.23

SXT-R, SXT-resistant; SXT-S, SXT-susceptible; OR, odds ratio; CI, conﬁdence interval; IQR, interquartile range.
a
Data are n (%) unless otherwise stated.
b
Within 3 months of infection.
c
Within 1 month of infection.
d
Within 12 months of infection.

within the previous 12 months of collection of the index urine
culture as potential risk factors for SXT resistance.
After adjustments in the multivariate logistic regression, prior
UTI or urinary colonisation with SXT-R bacteria and prior SXT use
were the only two variables that were independently associated
with SXT resistance (Table 2).
A stratiﬁed antibiogram was developed for Enterobacteriaceae
urinary isolates based on the presence or absence of the
aforementioned risk factors for SXT resistance. In the majority
of patients without risk factors for resistance, the probability of
SXT resistance among Enterobacteriaceae urinary isolates was 13%.
This probability increased to 73% in patients with both risk factors
for SXT resistance (Fig. 1).
Multidrug resistance was present in 82 isolates (23.4%) overall
and was more common among SXT-R isolates (40/71; 56.3%)
compared with SXT-S isolates (42/280; 15.0%) (P < 0.001). When
examining nitrofurantoin susceptibility (n = 340 isolates), 107
isolates (31.5%) were nitrofurantoin-non-susceptible. Resistance
to nitrofurantoin was uncommon among tested E. coli strains (10/
210; 4.8%). There was no difference in nitrofurantoin resistance
rates between SXT-R and SXT-S bacteria [21/68 (30.9%) vs. 86/272
(31.6%)]. However, nitrofurantoin resistance among E. coli isolates
was more common in SXT-R compared with SXT-S isolates [8/52
(15.4%) vs. 2/158 (1.3%)].
4. Discussion
The study demonstrated that prior urinary infection or
colonisation with a SXT-R bacteria and SXT use within the previous
year were predictors of bacterial resistance to SXT in patients with

community-onset UTI due to Enterobacteriaceae. The association
between prior SXT use and resistance is consistent with the results
of previous studies [20–24]. However, the ﬁnding that prior SXT
use may increase the risk of SXT resistance up to 1 year from
exposure is unique to the current study. The prolonged impact of
SXT on the microbiome and the increased risk of AMR in patients
with UTI for up to 1 year from exposure is not necessarily a feature
unique to SXT. A recent study demonstrated that ﬂuoroquinolone
use increased the risk of cUTI due to ﬂuoroquinolone-resistant
bacteria up to 1 year from exposure, with the highest risk of
resistance observed in patients who received ﬂuoroquinolones
within the past 3 months compared with 3–12 months from the
index cUTI [15]. An exploratory analysis of the current study did
not demonstrate a difference between timing of prior SXT use (i.e.
within past 3 months vs. 3–6 months vs. 6–12 months, etc.) and the
odds of SXT resistance, although this analysis may have been
underpowered (results not shown). This highlights the importance
of collecting prior antimicrobial use in patients with symptoms of
UTI prior to making empirical antimicrobial treatment decisions.
The association between prior urinary infection or colonisation
with SXT-R bacteria and SXT resistance in patients with UTI is
conceivable. A recent study demonstrated that prior urine culture
reports were useful in predicting current results in patients with
recurrent UTI [25]. Utilisation of prior microbiology data to guide
selection of empirical antimicrobial therapy of current infections
prior to availability of new culture results has also been described
in the setting of various infections [13,14,26].
Application of a patient-speciﬁc antibiogram for Enterobacteriaceae urinary isolates in the current study may improve SXT
utilisation and antimicrobial management in patients with UTI.

Table 2
Independent risk factors for trimethoprim/sulfamethoxazole (SXT) resistance in the multivariate logistic regression model.
Risk factor

aOR (95% CI)

P-value

Immunocompromised status
Recent hospitalisation within past 3 months
Prior urinary infection/colonisation with SXT-R bacteria within past 12 months
Prior SXT use within past 12 months
Prior ﬂuoroquinolone use within past 12 months

1.59 (0.61–4.51)
1.14 (0.58–2.22)
8.58 (3.92–18.81)
2.58 (1.13–5.89)
1.83 (0.84–3.97)

0.34
0.71
<0.001
0.02
0.13

aOR, adjusted odds ratio; CI, conﬁdence interval; SXT-R, SXT-resistant.
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Fig. 1. Resistance rates to trimethoprim/sulfamethoxazole (SMX/TMP) in stratiﬁed antibiogram based on patient-speciﬁc risk factors.

The probability of SXT resistance was only 13% in the absence of
prior urinary cultures for SXT-R bacteria and SXT use within the
past year. This preserves SXT as a potential treatment option for
acute cystitis in patients without risk factors since the probability
of SXT resistance in these patients does not exceed 20% as
recommended by the international management guidelines [4].
Although this threshold may seem arbitrary, a recent survey
suggested that clinical pharmacists across the USA were comfortable with agents with 80% susceptibility when recommending
empirical antimicrobial therapy for acute cystitis [27]. The low cost
and inclusion of SXT as a preferred antimicrobial agent in most
third-party insurers’ plans make SXT an attractive option in many
patients with acute cystitis. Moreover, this allows SXT use in
patients who may not be ideal candidates for nitrofurantoin or
fosfomycin therapy owing to low creatinine clearance, documented resistance in prior urine cultures or recent use of both
agents.
The results of the current study also have clinical implications
for patients with acute pyelonephritis in ambulatory settings. A
recent study demonstrated that the probability of ﬂuoroquinolone
resistance exceeded 50% in patients who used ﬂuoroquinolones
within the past 3 months and exceeded 30% if ﬂuoroquinolones
were used within the past 3–12 months [15]. Based on the current
results, SXT may be a better empirical option than ﬂuoroquinolones in these patients if they did not use SXT and did not have
prior UTI or urinary colonisation with SXT-R bacteria within the
past year. However, since the probability of SXT resistance still
exceeds 10% even in the absence of risk factors, patients with
pyelonephritis should receive one injection of ceftriaxone prior to
empirical SXT therapy [4].
In the era of increasing AMR, selection of empirical antimicrobial therapy based on overall antibiogram data has become
incredibly challenging. A patient-speciﬁc antibiogram that predicts the probability of AMR in each individual based on their own
risk factors may improve empirical antimicrobial selection in
patients with bacterial infections. The current study adds one more
clinical tool for prediction of AMR in patients with UTI.
This study has several limitations. First, it shares common
limitations of retrospective studies of missing undocumented
variables in electronic medical records or from hospitals outside of
the health system, and potentially failing to adjust for unknown
confounders. Second, the patient sample may have been biased to a
higher acuity population, as many of the patients were seeking
care at the emergency department. Approximately 30% of the
patients had a previous hospitalisation in the past 3 months, which

may have increased the likelihood of hospital-acquired bacteria.
However, hospitalisation alone without the receipt of antibiotics is
less likely to drive resistance. In addition, the study includes
patients from multiple facilities within the same healthcare
system in one geographic location. Multicentre studies may offer
a broader scale of microbiology and patient populations. External
validation of this SXT resistance tool may increase the generalisability of the current study results.
In summary, SXT remains an important option for treatment of
community-onset cystitis and pyelonephritis. Stratiﬁcation of
patients with UTI based on the probability of SXT resistance
allows using this antimicrobial agent in patients with a low
probability of resistance, such as those without prior urinary
infection/colonisation with SXT-R bacteria or SXT use in the
previous year. This allows the expansion of oral antimicrobial
treatment options for acute cystitis and pyelonephritis, which is
particularly helpful in patients who may not be eligible for
treatment with ﬁrst-line agents.
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